"Landmark Cancer Breakthrough: Gleevec's Pioneering Impact on Leukemia Treatment In a groundbreaking moment for cancer research, the US Food and Drug Administration (FDA) approved Gleevec in 2001 to treat a specific form of leukemia, marking a significant shift in the way the disease is managed. Gleevec, a targeted therapy, was the first medication of its kind to demonstrate remarkable effectiveness in treating chronic myeloid leukemia (CML), a previously incurable condition. The approval of Gleevec paved the way for a new generation of cancer treatments that focus on specific molecular targets, rather than relying solely on traditional chemotherapy. This pioneering achievement has had a lasting impact on cancer care, offering new hope to patients and their families around the world."
When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer care.
